Chronic Granulomatous Disease (CGD)

Immunology·MeSH: Granulomatous Disease, Chronic

Prevalence

0.5 / 100K

16 drugs in development·4 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Base-edited hematopoietic stem and progenitor cells	ENANTA PHARMACEUTICALS INC (ENTA)
Tocilizumab	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(7)

Drug	Company
Busulfan	ENANTA PHARMACEUTICALS INC (ENTA)
Pegfilgrastim	ENANTA PHARMACEUTICALS INC (ENTA)
Plerixafor	ENANTA PHARMACEUTICALS INC (ENTA)
Sirolimus	ENANTA PHARMACEUTICALS INC (ENTA)
Sirolimus	Merus N.V. (MRUS)
Sirolimus	Crinetics Pharmaceuticals, Inc. (CRNX)
Temsirolimus	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(7)

Drug	Company
Busulfan	Crinetics Pharmaceuticals, Inc. (CRNX)
Eltrombopag	Crinetics Pharmaceuticals, Inc. (CRNX)
Filgrastim	ENANTA PHARMACEUTICALS INC (ENTA)
Palifermin	ENANTA PHARMACEUTICALS INC (ENTA)
Palifermin	Merus N.V. (MRUS)
Plerixafor	Merus N.V. (MRUS)
Sirolimus	Structure Therapeutics Inc. (GPCR)

BioSniper tracks 16 drugs in development for Chronic Granulomatous Disease (CGD) across 4 companies.

There are 2 clinical trials targeting Chronic Granulomatous Disease (CGD) tracked by BioSniper.

The estimated prevalence of Chronic Granulomatous Disease (CGD) is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.